NEW YORK (TheStreet) -- Shares of Sarepta Therapeutics (SRPT) - Get Report  are down 2.41% to $20.63 this morning after the company reported a loss for the 2016 second quarter, meeting analysts' expectations.

The company reported a loss of $1.19 per share, or $54.8 million total. No revenue was recognized for the 2016 second quarter.

Analysts had estimates the losses.

Sarepta is a Cambridge, MA-based biopharmaceutical company.

The company is currently waiting for an FDA decision for a Duchenne muscular dystrophy drug, eteplirsen, but analysts at RBC Capital Markets said in a recent note that chances of approval are not favorable.

Sarepta Therapeutics stock has fallen 45% since the beginning of the year.

Separately, TheStreet Ratings rated this stock as a "sell" with a ratings score of D-.

The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity, weak operating cash flow, generally disappointing historical performance in the stock itself and poor profit margins.

You can view the full analysis from the report here: SRPT

Recently, TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this articles's author. 

Image placeholder title